Pinarayi Vijayan questions SMA drug distribution; SAT Hospital says only CDSCO-approved drugs used

The controversy began when reports emerged that a spinal muscular atrophy (SMA) medication, intended for children with a rare neuromuscular disorder, was being distributed in a manner that raised safety concerns. Chief Minister Pinarayi Vijayan described the health minister's handling of the situation as criminal and called for a formal investigation to determine whether procedural lapses had endangered patients. He emphasized that the state government has a duty to protect vulnerable citizens and that any deviation from established protocols must be examined thoroughly.

In response, officials at SAT Hospital, the facility at the center of the dispute, issued a statement asserting that all SMA treatments administered were sourced from the Central Drugs Standard Control Organization (CDSCO) and complied with national regulatory standards. The hospital's director highlighted that the drugs were procured through authorized channels and that the staff followed prescribed dosage guidelines. He also noted that the institution maintains detailed records of each patient's treatment to ensure transparency and accountability.

The disagreement has prompted calls from medical associations for clearer guidelines on the distribution of high‑cost specialty drugs. Critics argue that the episode underscores the need for stronger oversight mechanisms to prevent similar incidents in the future. The state health department has indicated that it will cooperate with any investigative body and that it is reviewing its internal procedures. The outcome of the inquiry could shape policy on drug procurement and patient safety across the region.